Salarius Pharmaceuticals Inc Stock Price, News & Analysis

Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation, accessible to registered attendees starting at 7 a.m. ET on September 13, will cover the company's business overview, recent achievements, and clinical milestones for seclidemstat, an LSD1 inhibitor in trials for Ewing sarcoma and hematologic cancers. Salarius will also engage in one-on-one meetings with investors and pharmaceutical executives.

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) has announced that CEO David Arthur will present at the Diamond Equity Research Emerging Growth Invitational Conference on August 17, 2021, at 11 a.m. ET. The presentation will cover the company's business highlights, recent achievements, and future clinical milestones for seclidemstat, an oral LSD1 inhibitor. Salarius is advancing a Phase 1/2 clinical trial for Ewing sarcoma and other cancers. Interested participants can register for the event at no cost, with a recording available post-event on Salarius' website.

Salarius Pharmaceuticals (Nasdaq: SLRX) recently reported significant developments during Q2 2021, including the commencement of clinical trials for its lead drug candidate, seclidemstat, in various cancer types. The company has cash reserves of $33.1 million, enough to fund ongoing clinical programs. Initial findings presented at ASCO 2021 indicated preliminary efficacy for seclidemstat, with a manageable safety profile. A Phase 1/2 trial is underway for treating hematologic cancers in collaboration with MD Anderson Cancer Center, while multiple new sites and patient groups are being added for sarcoma studies.

Salarius Pharmaceuticals (Nasdaq: SLRX) will host a conference call and live audio webcast on August 5, 2021, at 10:00 a.m. ET to discuss its second quarter and year-to-date 2021 financial results. The conference call can be accessed via phone or through the company’s website. Salarius is focused on developing cancer therapies, particularly its lead candidate, seclidemstat, which is in a Phase 1/2 clinical trial for various sarcomas, including Ewing sarcoma. The company has received several designations from the U.S. FDA to support its work.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced that Dr. Aundrietta Duncan will present on seclidemstat at the Epigenetic Therapeutic Targets Summit on July 14, 2021. Her talk, titled 'Targeting FET-Rearranged Sarcomas Through Inhibition of LSD1', will explore the potential of LSD1 inhibition in treating Ewing-related sarcomas. Currently, seclidemstat is in a Phase 1/2 study for Ewing sarcoma and other related cancers, and has received multiple FDA designations. The presentation will be accessible to registered participants and later available on Salarius' website.

Salarius Pharmaceuticals (Nasdaq: SLRX) has expanded its ongoing clinical trial for seclidemstat to nine trial sites, including Fox Chase Cancer Center. The trial focuses on patients with relapsed or refractory Ewing sarcoma and advanced FET-rearranged sarcomas. Patient recruitment is underway, targeting safety and efficacy with three distinct patient arms. Seclidemstat, designed to inhibit the LSD1 enzyme, has shown promise in combination therapies, especially with topotecan and cyclophosphamide. Results are anticipated in 2022.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the 2021 Ladenburg Thalmann Healthcare Conference on July 13, 2021, at 3 p.m. ET. The presentation will cover the company's advancements in cancer therapies, with a focus on seclidemstat, currently in Phase 1/2 trials for Ewing sarcoma and hematologic cancers. Seclidemstat has received multiple designations from the FDA, demonstrating its potential in treating pediatric and other cancers. A recording of the presentation will be available post-event.

Salarius Pharmaceuticals will host a virtual event on June 21, 2021, at 2:00 PM ET to discuss its lead drug candidate, seclidemstat. This event aims to highlight the scientific basis and clinical development of seclidemstat, an oral inhibitor of lysine-specific histone demethylase 1 (LSD1), crucial in cancer progression. The event will feature industry experts and will be accessible via audio webcast. Seclidemstat is being studied for its potential in treating pediatric cancers and advanced solid tumors, including Ewing sarcoma, with several FDA designations including Fast Track and Orphan Drug.

Salarius Pharmaceuticals (Nasdaq: SLRX) has initiated a Phase 1/2 clinical trial to evaluate seclidemstat as a treatment for Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). This trial, led by Dr. Guillermo Montalban-Bravo at MD Anderson Cancer Center, aims to establish the maximum tolerated dose and assess safety when combined with azacytidine. The study follows promising preclinical results showing anti-proliferative effects of seclidemstat in blood cancers, highlighting a potential new treatment avenue for patients with limited options.